Summary Tirzepatide is the generic name for the drug
Again, like other GLP-1 analogues, semaglutide should not be used in people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 1, or with a history of pancreatitis
The STEP 1 trial showed average weight loss of 14.9% over 68 weeks
While 73% of Americans are either overweight or have obesity, there are open questions about the use of GLP-1s in people who are not overweight will these medications cause excess weight loss and, in particular, excess muscle loss
Thanks for having me on
Insurance concierge: Hands-on support to navigate coverage for Ozempic, Wegovy, and Zepbound Labs included: Diagnostic testing included to tailor dosing and safety checks Medication choice: Access to brand-name GLP-1s and compounded alternatives when appropriate Personalized plans: Protocols customized to your lab results, history, and tolerance Flexible app-based care: Ongoing telehealth with no long-term commitment Lifestyle coaching: Built-in guidance for nutrition, habits, and sustainable change Heads up on common pitfalls elsewhere: some programs bill quarterly up front, exclude medication costs, offer only injectables, rely on nurse-led coaching, and use compounded GLP-1s that are not FDA-approved or available in every state